26
|
|
27
|
Carlson SE, Salem N. Essentiality of omega 3 fatty acids in growth and development of infants. World Rev Nutr Diet 2015; 66:74-86. [PMID: 2053367 DOI: 10.1159/000419281] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
28
|
|
29
|
Blanchard P, Faivre L, Lesaunier F, Salem N, Mesgouez-Nebout N, Deniaud-Alexandre E, Ferrero J, Houédé N, Habibian M, Fizazi K. PD-0046: Outcome according to pelvic radiotherapy in the GETUG 12 phase III trial for high-risk localized prostate cancer. Radiother Oncol 2015. [DOI: 10.1016/s0167-8140(15)40046-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Phillips LR, Salem BE, Jeffers KS, Kim H, Ruiz ME, Salem N, Woods DL. Developing and Proposing the Ethno-Cultural Gerontological Nursing Model. J Transcult Nurs 2014; 26:118-28. [DOI: 10.1177/1043659614563615] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
By 2050, for the first time in U.S. history, almost half of elders will be from ethnic minority groups. To meet the needs of this rapidly diversifying population, nurses need to be able to marry transcultural nursing knowledge with gerontological nursing knowledge. The purpose of this article is to propose a new theoretical model for explaining health outcomes and health responses for older individuals in unique ethno-cultural groups and to discuss implications and applications of the model to transcultural gerontological nursing practice and research. The discussion will include (1) an overview of currently available theoretical knowledge in the area, (2) a description of the theory development process, (3) presentation of the proposed ethno-cultural gerontological nursing theoretical model, and (4) discussion of how this model can enhance nursing’s contributions to reducing health disparities. This model is presented not as a finished product but as a basis for future discussion and refinement.
Collapse
|
31
|
Gravis G, Chanez B, Derosa L, Beuselinck B, Laguerre B, Barthelemy P, Brachet P, Lobbedez FJ, Escudier B, Stewart G, Harrison D, Laird A, Vasudev N, Ralph C, Larkin J, Lote H, Walz J, Thomassin J, Salem N, Boher J. Impact on Overall Survival of Glandular Metastasis in Patients with Metastatic Clear Cell Renal Cell Carcinoma. on Behalf of the Renal Cross Channel Group. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu337.18] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Kim H, Woods DL, Phillips LR, Ruiz ME, Salem B, Jeffers-Skrine K, Salem N. Nursing Assistants’ Communication Styles in Korean American Older Adults With Dementia. J Transcult Nurs 2014; 26:185-92. [DOI: 10.1177/1043659614547200] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
As ethnic diversity increases in the United States with the anticipated increase in dementia, it is critical to understand the implications of dementia and culturally appropriate communication for ethnic minority older adults with dementia. Utilizing the Ethno-Cultural Gerontological Nursing model and the Progressively Lowered Stress Threshold model, this article describes the relationship between nursing assistants’ communication style and behavioral symptoms of dementia, focused on Korean American older adults with dementia residing in nursing homes. The discussion includes reviewing currently available studies, nursing implications, and suggestions for future studies.
Collapse
|
33
|
García-Bastidas F, Ordóñez N, Konkol J, Al-Qasim M, Naser Z, Abdelwali M, Salem N, Waalwijk C, Ploetz RC, Kema GHJ. First Report of Fusarium oxysporum f. sp. cubense Tropical Race 4 Associated with Panama Disease of Banana outside Southeast Asia. PLANT DISEASE 2014; 98:694. [PMID: 30708524 DOI: 10.1094/pdis-09-13-0954-pdn] [Citation(s) in RCA: 56] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Fusarium wilt or Panama disease of banana, caused by Fusarium oxysporum f. sp. cubense (Foc), is among the most destructive plant diseases (3). Race 1 ravaged 'Gros Michel'-based export trades until the cultivar was replaced by resistant Cavendish cultivars. However, a new variant of Foc, tropical race 4 (TR4), was identified in Southeast Asia in 1992 and has spread throughout the region (3). Cavendish clones, which are most important in subsistence and export production, are among the wide range of cultivars that are affected, and there is a huge concern that TR4 will further disseminate in Africa since its presence was announced in November 2013 and move into Latin America, thereby threatening other vital banana-growing regions. In Jordan, Cavendish bananas are produced on 1,000 to 1,500 ha in the Jordan Valley (32°N, 35.5°E). In 2006, symptoms of Fusarium wilt were observed and sampled for the isolation of Foc. On half-strength PDA amended with 100-ppm streptomycin sulfate, pale salmon-colored colonies with floccose mycelia developed consistently from surface-disinfested xylem. Single microconidia from these colonies were transferred to half-strength PDA, and conidia and mycelia from these monospore colonies were stored at -80°C in 15% glycerol. On banana leaf agar (Co60-irradiated leaf tissue on water agar), isolates resembled F. oxysporum phenotypically by producing infrequent three- to five-celled macroconidia, copious, usually aseptate microconida on monophialides, and terminal and intercalary chlamydospores after 2 weeks (2). With nitrate-nonutilizing (nit) mutants and testers for different vegetative compatibility groups (VCGs), each of seven examined monospore isolates were placed in VCG 01213, which contains only strains of TR4 (3). Total DNA was extracted from six isolates and PCR analyses, which confirmed their identity as TR4 (1). Subsequently, one of the isolates (JV11) was analyzed for pathogenicity. Inoculum production and inoculation were according to (1) by dipping (30 min) root-wounded 10-week-old plants of the Cavendish cv. Grand Naine in 2 liters of spore suspension (1.0 × 106 spores/ml). Inoculated plants were then placed in sand in 3-liter pots under 28°C, 70% relative humidity, and a 16/8-h light/darkness photoperiod. Sets of three plants were each treated with either JV11 or two TR4 controls (isolate II-5 and a strain isolated from an affected Cavendish plant in Mindanao, Philippines, both of which were diagnosed as TR4 by PCR and pathogenicity analyses). Control sets were either treated with race 1 originating from Cruz das Almas, Bahia, Brazil (1), or water. After 2 weeks, plants inoculated with JV11 and TR4 controls produced typical symptoms of Fusarium wilt. After 4 weeks, tissue was collected from all plants and plated on Komada's medium. TR4 was directly confirmed by PCR (1), either directly from symptomatic plants (JV11 and TR4 controls), or from isolates that were recovered from these plants. Nothing was re-isolated from race 1 inoculated plants and water controls, which remained asymptomatic. This is the first report of TR4 affecting Cavendish outside Southeast Asia, is its northernmost outbreak, and represents a dangerous expansion of this destructive race. Currently, 80% of the Jordan Valley production area is affected by Fusarium wilt, and 20 to 80% of the plants are affected in different farms. References: (1) M. A. Dita et al. Plant Pathol. 59:348, 2010. (2) J. F. Leslie and B. A. Summerell. The Fusarium Lab Manual. Blackwell, Ames, 2006. (3) R. C. Ploetz. Phytopathology 96:653, 2006.
Collapse
|
34
|
Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxén Irving G, Eriksdotter M, Hjorth E, Schultzberg M, Vessby B, Wahlund LO, Salem N, Palmblad J. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. J Intern Med 2014; 275:428-36. [PMID: 24410954 DOI: 10.1111/joim.12166] [Citation(s) in RCA: 102] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Little is known about the transfer of essential fatty acids (FAs) across the human blood-brain barrier (BBB) in adulthood. In this study, we investigated whether oral supplementation with omega-3 (n-3) FAs would change the FA profile of the cerebrospinal fluid (CSF). METHODS A total of 33 patients (18 receiving the n-3 FA supplement and 15 receiving placebo) were included in the study. These patients were participants in the double-blind, placebo-controlled randomized OmegAD study in which 204 patients with mild Alzheimer's disease (AD) received 2.3 g n-3 FA [high in docosahexaenoic acid (DHA)] or placebo daily for 6 months. CSF FA levels were related to changes in plasma FA and to CSF biomarkers of AD and inflammation. RESULTS At 6 months, the n-3 FA supplement group displayed significant increases in CSF (and plasma) eicosapentaenoic acid (EPA), DHA and total n-3 FA levels (P < 0.01), whereas no changes were observed in the placebo group. Changes in CSF and plasma levels of EPA and n-3 docosapentaenoic acid were strongly correlated, in contrast to those of DHA. Changes in DHA levels in CSF were inversely correlated with CSF levels of total and phosphorylated tau, and directly correlated with soluble interleukin-1 receptor type II. Thus, the more DHA increased in CSF, the greater the change in CSF AD/inflammatory biomarkers. CONCLUSIONS Oral supplementation with n-3 FAs conferred changes in the n-3 FA profile in CSF, suggesting transfer of these FAs across the BBB in adults.
Collapse
|
35
|
Simopoulos AP, Leaf A, Salem N. Workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 Fatty acids. Asia Pac J Clin Nutr 2014; 8:300-1. [PMID: 24394233 DOI: 10.1046/j.1440-6047.1999.00123.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
36
|
Ibrahim JN, Jounblat R, Delwail A, Abou-Ghoch J, Salem N, Chouery E, Megarbane A, Lecron JC, Medlej-Hashim M. PW01-023 – Ex vivo PBMC cytokine profile in FMF patients. Pediatr Rheumatol Online J 2013. [PMCID: PMC3952649 DOI: 10.1186/1546-0096-11-s1-a76] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Salem N, Darreon J, Benkemouche A, Charrier N, Brenot-Rossi I, Madroszyck A. Évaluation précoce de la réponse métabolique par TEP-scanographie après radiothérapie hypofractionnée thoracique. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.07.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Gilabert M, Provansal M, Cappiello M, Walz Y, Salem N, Tarpin C, Brunelle S, Thomassin J, Gravis G. Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma. Br J Cancer 2013; 109:1750-4. [PMID: 24045668 PMCID: PMC3790170 DOI: 10.1038/bjc.2013.516] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Revised: 08/06/2013] [Accepted: 08/09/2013] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Sunitinib is a tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC). Few data evaluated severe buccodental adverse events. The aim of this study was to evaluate sunitinib buccodental toxicity in patients with metastatic RCC and to compare it with that of standard chemotherapy in patients with other solid cancers. METHODS Patients with RCC treated with sunitinib and patients with other solid tumours treated with chemotherapy were followed for 3 months. Data on dental appliances, oral hygiene/care practices before and during treatment were collected. RESULTS A total of 116 patients were included (58 RCC treated by sunitinib: group S, and 58 treated by chemotherapy: group C). No differences in dental care habits were noted before treatment. In group S, patients reported significantly more frequent pain (P<0.01), teeth instability (P=0.01), gingival bleeding (P=0.01) and change in teeth colour (P=0.02). In all, 58% of patients in this group had to modify their diet (P<0.01). Frequency of dentist visits for teeth removal was increased (25% vs 8%, P=0.01). CONCLUSION Sunitinib seems to increase buccodental toxicity as compared with chemotherapy. This finding emphasises the need for optimal dental care and standardised dental follow-up in patients treated with sunitinib.
Collapse
|
39
|
Dubray B, Mezzani-Saillard S, Édet-Sanson A, Ménard JF, Modzelewski R, Thureau S, Meyer ME, Jalali K, Bardet S, M’Vondo CM, Houzard C, Mornex F, Olivier P, Faure G, Rousseau C, Mahé MA, Gomez P, Brenot-Rossi I, Salem N, Vera P. La SUVmax (standard uptake value maximale) mesurée en cours de radiothérapie pour cancer bronchique non à petites cellules est prédictive de la survie sans récidive à un an : étude prospective et multicentrique. Cancer Radiother 2013. [DOI: 10.1016/j.canrad.2013.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Darréon J, Salem N, Charrier N, Benkemouche A. PET-scan premature evaluation after hypofractionated thoracic radiotherapy. Phys Med 2013. [DOI: 10.1016/j.ejmp.2013.08.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
41
|
Chouery E, Abou-Ghoch J, Corbani S, El Ali N, Korban R, Salem N, Castro C, Klayme S, Azoury-Abou Rjeily M, Khoury-Matar R, Debo G, Germanos-Haddad M, Delague V, Lefranc G, Mégarbané A. A novel deletion in ZBTB24 in a Lebanese family with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. Clin Genet 2012; 82:489-93. [PMID: 21906047 DOI: 10.1111/j.1399-0004.2011.01783.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
The immunodeficiency, centromeric instability and facial anomalies (ICF) syndrome is a rare autosomal recessive disease characterized by targeted chromosome breakage, directly related to a genomic methylation defect. It manifests with phenotypic and clinical variability, with the most consistent features being developmental delay, facial anomalies, cytogenetic defects and immunodeficiency with a reduction in serum immunoglobulin levels. From the molecular point of view, ICF syndrome was always divided into ICF type I (ICF1) and ICF type 2 (ICF2). Mutations in DNMT3B gene are responsible for ICF1, while mutations in ZBTB24 have been reported to be responsible for ICF2. In this study, we describe a Lebanese family with three ICF2 affected brothers. Sanger sequencing of the coding sequence of ZBTB24 gene was conducted and revealed a novel deletion: c.396_397delTA (p.His132Glnfs*19), resulting in a loss-of-function of the corresponding protein. ZBTB24 belongs to a large family of transcriptional factors and may be involved in DNA methylation of juxtacentromeric DNA. Detailed molecular and functional studies of the ZBTB24 and DNMT3B genes are needed to understand the pathophysiology of ICF syndrome.
Collapse
|
42
|
Moureau-Zabotto L, Ortholan C, Hannoun-Lévi JM, Tessier E, Cowen D, Salem N, Lemanski C, Ellis S, Resbeut M. Influence du boost en curiethérapie dans la prise en charge des cancers du canal anal avec envahissement ganglionnaire initial (étude CORS-03). Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
43
|
Benkemouche A, Salem N, Farnault B, Fau P, Darréon J, Nomikossoff N, Ferré M, Mailleux H, Zaccariotto A, Resbeut M. Comparaison des résultats dosimétriques de l’arcthérapie volumétrique modulée (ElektaVMAT) et de la tomothérapie (Hi-Art) dans les cancers de la prostate. Cancer Radiother 2012. [DOI: 10.1016/j.canrad.2012.07.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
44
|
Sabatier R, Eymard JC, Walz J, Deville JL, Narbonne H, Boher JM, Salem N, Marcy M, Brunelle S, Viens P, Bladou F, Gravis G. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann Oncol 2012; 23:714-721. [PMID: 21653681 DOI: 10.1093/annonc/mdr275] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
BACKGROUND Sunitinib is a standard of care for metastatic renal cell carcinoma (mRCC). Hypothyroidism is frequently observed under sunitinib therapy. This study was conducted to prospectively determine the correlation between thyroid function and progression-free survival (PFS) in this population. PATIENTS AND METHODS One hundred and eleven mRCC patients treated with sunitinib were evaluated for serum thyroid-stimulating hormone (TSH) and T4 levels before treatment and every 6 weeks during treatment. Survival was analysed according to a landmark method with a cut-off of 6 months, excluding early progressive or early-censored patients. RESULTS Out of the 102 patients with normal baseline thyroid function, 53% developed thyroid dysfunction, including 95% hypothyroidisms out of which 90.9% received L-thyroxine replacement. Median time to TSH alteration was 5.4 months. Median PFS was 11.7 months for the entire population. Median PFS was not different between the groups with abnormal or normal thyroid function after 6 months of treatment (18.9 and 15.9 months, respectively, log-rank P = 0.94, hazard ratio = 1.02, 95% confidence interval = 0.54-1.93). There was no difference even after adjustment for Memorial Sloan-Kettering Cancer Centre classification and therapy line. CONCLUSIONS Abnormal thyroid function with hormonal substitution did not increase survival in our population, independent of initial prognosis and previous treatments. Larger comparative studies are deserved to validate these conclusions.
Collapse
|
45
|
Michel V, Houvenaeghel G, Bannier M, Tallet A, Minsat M, Lambaudie E, Salem N, Butarelli M, Resbeut M. P3-12-05: Breast Cancer Recurrence: 2nd Conservative Treatment Versus Mastectomy. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-12-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Objectives: Mastectomy (Mt) is considered standard treatment for isolated local recurrence (LR) of breast carcinoma. The aim of our study was to evaluate a second conservative treatment (defined as lumpectomy followed by interstitial brachytherapy (LpIB)) and to determine if it compares favorably with the current standard treatment. Materials and methods: Between January 1981 and December 2009, 348 patients were treated to the Paoli Calmettes Institute (IPC) for an isolated LR: 232 (66,7 %) underwent Mt, 62 (17,8 %) received a second radio-surgical conservative treatment (LpIB) and 54 (15,5 %) a 2nd single surgical treatment (Lp).
We classified each population according to the well known prognosis factors.
Then, populations Mt and LpIB were matched taking into account these criteria to compare the overall survival (OS), metastasis free survival (MFS) and 2nd local recurrence free survival according to the treatment delivered.
Results: On 348 reviewed patients, with a median follow-up of 73,3 months, 65 patients died (42/232 Mt, 8/62 TecCur, 15/54 Tec) and 100 presented metastasis (64/232 Mt, 15/62 TecCur, 21/54 Tec). There was no difference in MFS for the 2 groups, LpIB and Mt (80 % at 5 years) and the OS was non significantly better in the group LpIB compared to the group Mt (90 % and 82 % at 5 years respectively, p=0,28), whereas in the LpIB group 17% and 30% presented a relapse at 5 years and 10 years respectively.
They subsequently underwent a salvage mastectomy.
Worse results were obtained with lumpectomy alone (OS = 72 % and MFS = 68 % at 5 years) compared with 2 other option treatments.
Conclusion: A second conservative treatment for breast cancer recurrence, i.e. lumpectomy and interstitial brachytherapy, is possible for selected patients, without any negative impact on overall survival, nor metastasis free survival.
Keywords: Local recurrence, interstitial brachytherapy, lumpectomy, conservative treatment, mastectomy, overall survival, metastasis free survival, breast carcinoma.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-12-05.
Collapse
|
46
|
Cowen D, Duberger T, Hannoun-Levi J, Azria D, Salem N, Ellis S, Teissier E, Resbeut M. Adenoid Cystic Carcinoma Of The Head and Neck: Retrospective Series Of 169 Cases. Int J Radiat Oncol Biol Phys 2011. [DOI: 10.1016/j.ijrobp.2011.06.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
47
|
Gilabert M, Provansal M, Cappiello M, Walz J, Brunelle S, Salem N, Gravis G. Self assessment of buccodental toxicity: Comparison of patients with metastatic renal cell carcinoma (RCC) treated with sunitinib with patients treated with chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
48
|
Champetier C, Hannoun-Levi JM, Resbeut M, Azria D, Salem N, Tessier E, Ellis S, Cowen D. Radiothérapie postopératoire dans les sarcomes utérins : étude rétrospective multicentrique. Cancer Radiother 2011; 15:89-96. [DOI: 10.1016/j.canrad.2010.05.005] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2009] [Revised: 05/04/2010] [Accepted: 05/11/2010] [Indexed: 11/29/2022]
|
49
|
Walz J, Rybikowski S, Gabbay G, Salem N, Gravis G, Bladou F. Intérêt de la robotique dans le traitement du cancer du rein. ONCOLOGIE 2011. [DOI: 10.1007/s10269-010-1973-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
50
|
Tallet AV, Farnault BP, Moureau-Zabotto LV, Esterni BA, Salem N, Gonçalves A, Houvenaeghel GF, Jacquemier JD, Resbeut M. Abstract P6-03-03: Could We Reduce the Number of Exams in the Follow-Up of Breast Cancer Survivors? Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-03-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background. The aim of this retrospective study was to determine by which way was diagnosed any breast cancer recurrence after the end of the adjuvant treatment and to draw guidelines for exams for the follow-up. Materials and methods. Between January 1995 to December 2005, 5419 patients were treated for non metastatic breast cancer in our institute, out of which 662 experienced a relapse either local or metastatic. The charts of 608 of these patients were analysable, and retrospectively reviewed. For each case, we looked at the exams or clinical symptom which revealed the recurrence.
Results. Among the 608 patients who recurred, 173 patients (28%) experienced an isolated local relapse, while 12 experienced a contralateral breast cancer (2%), 423 experienced either a metastatic or metastatic plus local relapse (65% and 5%, respectively). Local relapses were detected in most of cases either clinically (42%) or on mammography and mammary ultrasound (US) (55%). An isolated increase of blood tumor marker (CA 15.3) revealed the relapse in 24% of cases (in 33% of cases for distant relapses and 3% for isolated local relapses). The remaining 67% of cases with metastases were diagnosed by clinical symptoms in 47% of cases, imaging in 22% of cases (bone scan in 6%, liver US 5%, mammography 1%, TDM 5%, chest X-ray 2%). In these cases of radiographically detected metastases clinical exam and/or tumor markers levels were abnormal in 42% of cases.
Conclusion. A follow-up with a systematically clinical exam, mammography and mammary US, and blood tumor markers assessment permits the diagnosis of 100 percent of local relapse, 100% of contralateral breast cancer, and 89% of metastatic disease. Thus imaging exams could be avoided routinely, with less stress for the patient and improvement of the health cost.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-03-03.
Collapse
|